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The voltage-gated Na + channel plays an important role in the membrane excitability of cardiomyocytes [1] [2] [3] . As a major Na + channel isoform, the Na V 1.5 α subunit encoded by the SCN5a gene determines the cardiac rapid depolarization characteristic of ventricular myocytes and drives subsequent electrical propagation throughout the heart [1, 3] . Heterozygous deletion of SCN5a leads to prolongation of both the PRinterval and QRS complex as well as the ventricular tachycardia in mice [4] . Numerous studies have shown that the dysfunction of Na + channels contributes to the development of life-threatening ventricular arrhythmias in both inherited ion channelopathies and acquired cardiac diseases [1] [2] [3] [5] [6] [7] [8] . Mutations of SCN5a gene alter the function of the Na + channel and have been linked to Brugada syndrome, long QT syn-Na + channel activity is finely regulated by complex molecular mechanisms [11, 12] . Na + channel β subunits, ankyrin-G, fibroblast growth factor homologous factor 1B, caveolin-3, E3 ubiquitin-protein ligase Nedd4, glycerol-3-phosphate dehydrogenase 1-like protein, plakophilin-2, MOG1, a multiprotein complex composed of syntrophins and dystrophin [13] interact with Na V 1.5 to regulate Na + channel activity [14] [15] [16] [17] [18] [19] [20] [21] . Na V 1.5 is directly phosphorylated by Ca 2+ /calmodulindependent protein kinase II (CaMKII) and protein kinase A, resulting in changes of Na + channel activity [11] . Na V 1.5 requires ankyrin-Gbinding for normal physiological function [22] and its localization at the intercalated disks is required for β (IV)-spectrin-dependent targeting of CaMKII to a critical phosphorylation site, S571, in Na V 1.5 [23] . At the transcription level, NF-KappaB and TBX5 directly affect the SCN5a promoter activity and alter Na V 1.5 expression [12, 24] . NFKappaB functions as a suppressor [12] while TBX5 functions as an activator of SCN5a gene transcription in cardiac cells [24] . Accumulating evidence indicates that Forkhead box O (FoxO) transcription factors are critical in maintaining cardiac function and mediating oxidative stress [25] . Although FoxO1, 3, and 4 are all expressed in the heart, FoxO1 is the main isoform found in the adult heart [26] . The transcriptional activities of FoxOs largely depend upon their nuclear localization [27] . Deacetylation or phosphorylation of FoxO proteins typically determines their localization in either the nuclei or cytoplasm [27] . Generally, FoxO proteins directly bind to consensus DNA sequences and regulate the expression of target genes. The proximal regions of the mouse, rat, and human SCN5a promoters have FoxO-binding insulin response elements, indicating that FoxO1 may regulate Na V 1.5 expression [27] . Indeed, our previous studies have shown that FoxO1 reduces Na V 1.5 expression in vitro by binding to the SCN5a promoter and inhibiting its activity in HL-1 cardiomyocytes [27] . In our current study, we characterized the cardiac electrophysiological phenotype of mice with tamoxifen-induced and cardiac-specific deletion of FoxO1 and defined the in vivo role of FoxO1 in the regulation of cardiac Na + channel activity.
Methods

Polymerase chain reaction (PCR)
DNA was extracted from mouse-tails or hearts using Genomic DNA kit (QIAGEN) following the manufacturer's instruction. Two pairs of primers (forward: 5′-CTA GGC CAC AGA ATT GAA AGA TCT-3′, reverse:  5′-GTA GGT GGA AAT TCT AGC ATC ATC C-3′; forward: 5′-GCG GTC TGG  CAG TAA AAA CTA TC-3′, reverse: 5′-GTG AAA CAG CAT TGC TGT CAC  TT-3′) were used to determine the presence of Cre, while two additional pairs of primers (forward: 5′-GCT TAG AGC AGA GAT GTT CTC AGA TT-3′, reverse 1: 5′-CCA GAG TCT TCG TAT CAG GCA AAT AA-3′, and reverse 2: 5′-CAA GTC CAT TAA TTC AGC ACA TTG A-3′) were employed to determine the presence of LoxP sites flanking FoxO1 exon 2 and confirm deletion of exon 2.
Reverse transcription PCR (RT-PCR)
Using RNeasy Fibrosis Tissue kit (QIAGEN) and following the manufacturer's instruction, total RNA was extracted from adult mouse FoxO1 +/+ and FoxO1 −/− ventricles as well as the peri-infarct (borderzone) region defined as the 2-mm area encircling the area of pathologic infarction of the mouse hearts with anterior descending artery ligation or ventricular tissue from the hearts with a sham procedure. The RNA sample was then reversely transcribed to the first-strand cDNA using a high capacity cDNA reverse transcription kit (AB Applied Biosystems). Semi-quantitative RT-PCR was performed to measure the mRNA expression levels of Na V 1.5, Na + channel β subunits, connexin 43 (Cx43), and GAPDH in ventricular tissue. The primer sequences used to amplify the cDNA of these genes are provided in Supplemental Table 1 .
Western blotting
Western blot analysis was performed on the proteins extracted from mouse ventricles with FoxO1 +/+ and FoxO1
−/−
. Tissue from the periinfarct (border-zone) region, defined as the 2-mm area encircling the area of pathologic infarction of the wild mouse hearts with anterior descending artery ligation, or ventricular tissues from the mice with the sham procedure were used as well. Ventricular tissues were homogenized in cell lysis buffer (Cell Signaling Technology, Inc.). Fifteen to thirty micrograms of protein were equally loaded on 10% SDS polyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were blocked with 5% non-fat milk for 1 h, and then incubated with the indicated primary antibody overnight at 4°C. After one-hour incubation with the appropriate secondary antibody, the specific signals were revealed by enhanced chemiluminescence reagent (Pierce). Primary antibodies used in this study include rabbit anti-FoxO1 polyclonal (Cell Signaling, 1:1000 for Western blot and 1:200 for immunohistochemistry), rabbit anti-Na V 1.5 polyclonal (Alomone Labs, 1:500), rabbit anti-SCN3b polyclonal antibody (Abcam, 1:1000) and rabbit anti-GAPDH polyclonal (Millipore, 1:4000).
Whole-cell voltage clamp recording
Whole cell recording techniques were used to record Na + currents in isolated ventricular myocytes from adult mice. The methods used to isolate cardiomyocytes were described previously [27] . 
Immunohistochemical staining
Formalin fixed and paraffin embedded tissues from the left ventricular free wall of human hearts, including 3 non-failing controls without a history of heart diseases (NFH) and 3 failing ones with ischemic heart disease (IHD) were used for immunohistochemical staining. The research protocol was approved by the Institutional Review Boards at the University of Rochester. Four micrometer sections were cut from paraffin-embedded ventricular tissues and deparaffinized. Antigen retrieval was performed in sodium citrate buffer (pH 6.0) by heating to 99°C for 20 min with PT Link system by Dako (Carpinteria, CA). After quenching endogenous peroxidase activity with 3% H 2 O 2 , the sections were blocked with 10% non-immune goat serum (Invitrogen, Carlsbad, CA) and then incubated overnight with primary anti-FoxO1 antibody (1:200) at 4°C. The signals were amplified using the Histostain-SP Kit (Invitrogen) and detected with DAB substrate (Dako). Hematoxylin was used as a counterstain. Negative controls were incubated with serum instead of primary antibody under the same conditions.
Permanent left anterior descending coronary artery ligation surgery
Wild type mice were anesthetized with 2.0% isoflurane inhalation and placed onto a heating pad (half inch plexiglass between the animal and the heating pad). Oral tracheal intubation was performed with a PE 90 tube (o.d. 1.27 mm). Mechanical ventilation (tidal volume of 250 μl at 130 breaths per minute) was started and 1.5% isoflurane was used for maintenance of anesthesia. After intubation, a left thoracotomy was performed in the fourth intercostal space and the pericardium was vertically opened. The left anterior coronary artery (LAD) was ligated with 9-0 polypropylene sutures. After observation of ventricle blanching and ST-segment elevation in the electrocardiograms (ECGs), indicating successful occlusion of the artery, the chest was closed with 6-0 coated vicryl sutures. The skin was closed using 6-0 nylon, the anesthesia was stopped, and the mouse was allowed to recover for several minutes before the endotracheal tube was removed. Sham-operated animals served as surgical controls and were subjected to the same procedures as the experimental animals, except that the LAD was not ligated.
Electrocardiogram recording
The method used to record electrocardiograms from conscious and unrestrained mice is as described in our previous study [28] . Standard lead II surface ECGs were recorded in adult (N25 weeks) mice. Two electrodes were placed on the right anterior and superior, and left anterior and inferior chest surfaces, respectively, and were connected to a Bioamplifier (AD instrument, CO) through an electrical swivel 6 channel (Promed-Tec Inc. Bellingham, MA). ECG recordings were obtained at a frequency response of 0.05 to 500 Hz. Signals were digitized at 2 kHz and recorded on a personal computer.
Echocardiography
Echocardiography was performed in conscious adult (N25 weeks) mice using a high-resolution mouse echo machine (Visualsonics Vevo 2100 ultrasound system with an 18-38 MHz MS-400 transducer). The following parameters were measured digitally in M-mode: LV dimensions at diastole (LVDd) and systole (LVDs), and anterior and posterior wall thickness at diastole and systole. All measurements were averaged over five consecutive cardiac cycles. The observer conducting the measurement was blind to the experiments and genotypes.
Statistics
Results are presented as means ± standard error; the statistical significance of differences between groups was assessed using a two-tailed Student t-test and the significance level was set at p b 0.05. 
Results
Cardiac-specific
L/+ , and mhy6-MCM +/− /FoxO1 +/+ mice were generated from the further breeding, Tamoxifen was intraperitoneally injected in these mice for 5 consecutive days at a dose of 40 mg/kg/ day. All mice treated with tamoxifen injection survived the process and remained healthy. PCR was performed on DNA extracted from the hearts of the tamoxifen treated mice one month after the injections. Tamoxifen-mediated cardiac-specific deletion of FoxO1 (FoxO1 −/− ) induced by Cre was confirmed by the results presented in Supplemental Fig. 1 . FoxO1 −/− mice were healthy and did not exhibit any abnormal behaviors.
No cardiac hypertrophy identified in FoxO1
−/− heart Global knockout of FoxO3 has been reported to cause mouse cardiac hypertrophy [29] . To determine if FoxO1 deletion was able to induce cardiac hypertrophy, mouse heart/weight ratios and individual ventricular cell capacitances were determined. There was no significant difference in heart/body weight ratio (mg/g) between FoxO1
+/+ and FoxO1 −/− mice (3.8 ± 0.1, n = 7 versus 4.1 ± 0.1, n = 6) (Fig. 1A) .
After establishing whole-cell recordings, the currents were recorded to determine ventricular cell capacitance by depolarizing to − 60 mV and hyperpolarizing to − 80 mV from a holding potential (HP) of − 70 mV. The capacitances of ventricular myocytes isolated from FoxO1 −/− and FoxO1 +/+ mouse hearts were 117.1 ± 3.3 pF (n = 26) and 133.2 ± 9.9 pF (n = 18), respectively, and they were not statistically significantly different (Fig. 1B) . These findings indicate that cardiacspecific FoxO1 deletion does not result in cardiac hypertrophy in mice.
Heart function was not altered by FoxO1 deletion
To clarify the influence of FoxO1 deletion on mouse cardiac functions, echocardiography was performed. Representative M-mode images are shown in Fig. 1C . There were no significant differences in heart function parameters such as ejection fraction (EF) and fraction shortening (FS) between the FoxO1 −/− and FoxO1 +/+ mice (Supplemental Table 2 ). Furthermore, other echocardiography parameters such as LVPWs, LVPWd, LVIDs, and LVIDd did not significantly differ between FoxO1 −/− and FoxO1 +/+ mice (Supplemental Table 2 ). These Table 2 ).
findings indicate that FoxO1 does not significantly affect the cardiac functions nor cause hypertrophy in adult mice.
3.4. Deletion of FoxO1 induced an increase in both cardiac Na V 1.5 and β3 subunit expressions
FoxO1 negatively regulates Na V 1.5 expression in HL-1 cardiomyocytes [27] . To test the hypothesis that FoxO1 functions as a negative regulator of Na V 1.5 expression in mouse hearts, Western blot was performed on the protein extracted from FoxO1 +/+ and FoxO1 −/− mouse ventricles. As evidenced by Western blots ( Fig. 2A ) and quantitative analysis (Fig. 2B) , Na V 1.5 and β3 protein levels were significantly (p b 0.01, p b 0.05) increased and FoxO1 was significantly (p b 0.01) decreased in FoxO1 −/− hearts in comparison with FoxO1 +/+ hearts. Densitometry analyses of FoxO1, Na V 1.5, and β3 levels compared to GAPDH level showed that Na V 1.5 and β3 expressions were increased to 162% and 21% while FoxO1 expression was decreased to 84% in FoxO1
, compared to FoxO1 +/+ hearts (Fig. 2B ). These findings indicate that FoxO1 is a suppressor of both Na V 1.5 and β3 expressions in adult mouse hearts.
3.5. mRNA levels of Na V 1.5 and β3 subunit were increased in FoxO1
The QRS complex represents ventricular depolarization. Na + channel and Cx43 channel activities determine cardiac depolarization. Na + channel activity is primarily determined by a main α subunit, Na V 1.5; however, multiple β subunits also play roles in the regulation of this channel activity. Increased Na + channel activity due to elevated expression of Na V 1.5 protein was found in FoxO1 −/− mouse hearts and this contributed to the shortening of the QRS complex. Other components related to the electrical conduction between ventricular myocytes, such as β1, 2, 3, and 4 subunits as well as Cx43 were assessed in these cardiac FoxO1 deficient mice. RT-PCR analysis showed that the level of Na V 1.5 was significantly (p b 0.01) increased (Fig. 2C ). Interestingly, the mRNA level of the β3 subunit was also significantly (p b 0.01) increased, but β1, 2, and 4 and Cx43 levels were not changed in mouse hearts with deletion of FoxO1 in comparison with the control group ( Fig. 2C and D) . (Fig. 3B) . At the test potential of − 30 mV, the peak current density was 26.9 ± 1.4 pA/pF (n = 26) for FoxO1 −/− and 21.3 ± 1.8 pA/pF (n = 18) for FoxO1 +/+ . There was no significant shift of the test potential for the peak Na + current density between the two groups (Fig. 3B ).
3.7. Inactivation but not activation of Na + channel was accelerated by
FoxO1 deletion in ventricular myocytes
Time constants of activation (τ activation ) and inactivation (τ inactivation ) were analyzed by fitting the upstroke and decay traces of I Na using a mono-exponential function, respectively. As shown in Fig. 4B , there was no statistical difference in the τ activation of I Na between FoxO1 PCR was performed on the RNA extracts of mouse ventricles and the results showed that the mRNA levels of Na V 1.5 and β3 subunits but not β1, β2 and β4, and Cx43 were increased in FoxO1 −/− ventricles compared with FoxO1 +/+ group. Quantitative analyses of Na V 1.5, β subunits, and Cx43 mRNA levels relative to GAPDH revealed that Na V 1.5 and β3 subunit were significantly increased (p b 0.01).
indicating that deletion of FoxO1 accelerated the Na + channel inactiva- 
Recovery from the inactivation but not steady-state activation and inactivation of Na + channel was affected by FoxO1 deletion in ventricular myocytes
In order to determine whether there were any differences in Na + channel kinetics between FoxO1 +/+ and FoxO1 −/− ventricular myocytes, the steady-state activation, steady-state inactivation, and recovery from inactivation of I Na were recorded and analyzed. The voltage-dependent steady-state activation of the Na + channel was determined by a series of test potentials ranging from −90 to +60 mV at 0.1 Hz, from a holding potential of −100 mV (Fig. 5A) . These results showed that the voltagedependent activation of I Na was unchanged between FoxO1 +/+ and ( Fig. 5B) . Similarly, there were no changes in the voltage-dependent inactivation curves of I Na between the two groups. The half-maximal inactivation voltage and slope factor did not show a significant difference (− 70.93 ± 0.37 mV and 7.20 ± 0.33, n = 18 in FoxO1 −/− versus −71.60 ± 0.61 mV and 7.60 ± 0.53, n = 16 in FoxO1 +/+ ventricular myocytes). Recovery of I Na from inactivation was recorded by a pairedpulse with a variable inter-pulse duration (from 0 to 230 ms) at a holding potential of −100 mV. The curves of recovery from inactivation were obtained by normalizing the peak current from a test pulse (− 30 mV, 80 ms) to a conditioning pulse (−30 mV, 300 ms) and then fitting the data with the mono-exponential equation. These results (Fig. 5C) showed that the recovery of I Na from inactivation was significantly different between FoxO1 −/− and FoxO1 +/+ ventricular myocytes (Tau = 18.3 and 13.3; K slope factor = 0.075 ± 0.001 and 0.055 ± 0.000 in FoxO1 −/− versus in FoxO1 +/+ mice; n = 16 for each group; p b 0.05). These findings indicate that the deletion of FoxO1 leads to accelerated Na + channel recovery from inactivation.
Deletion of FoxO1 accelerated the depolarization of action potentials in ventricular myocytes
We further investigated whether FoxO1 deletion influenced the ventricular myocyte action potential. Action potentials were recorded at 1 Hz from FoxO1 (−86.8 ± 3.1 mV, n = 18) and FoxO1 +/+ (−89.0 ± 3.8 mV, n = 12).
Both action potential duration (APD) 50 and APD 90 were not significantly different (Fig. 6B) +/+ ventricular myocytes, respectively). These findings suggest that FoxO1 deletion induces an increase in Na V 1.5 expression and Na + channel activity, which leads to faster depolarization of action potentials.
QRS shortening in mice with cardiac deletion of FoxO1
Electrocardiogram (ECG) recording was performed on conscious and unrestrained mice (Fig. 7A) . No arrhythmias were observed in the mice with cardiac deletion of FoxO1 or controls without this deletion. Although the PR-, QTc-, and RR-intervals were not prolonged in the mice with cardiac deletion of FoxO1, the QRS complex and P wave were markedly different from the FoxO1 +/+ mice. The QRS complex was significantly shortened (p b 0.05) to 9.2 ± 0.3 ms (n = 5) in mice with cardiac deletion of FoxO1 from 10.2 ± 0.3 ms (n = 5) in the control group (Fig. 7B) ; the P wave amplitude was significantly (p b 0.05) increased to 0.17 ± 0.01 mV (n = 5) in mice with cardiac deletion of FoxO1 from 0.13 ± 0.01 mV (n = 5) in the control group.
3.11. Inverse relationship of nuclear FoxO1 to Na V 1.5 expression in ischemic hearts confirmed that Na V 1.5 is in vivo FoxO1 target during oxidative stress
In order to investigate the potential role of FoxO1 in the regulation of Na V 1.5 expression in the IHD, immunohistochemical staining was performed on ventricular tissue from human hearts with IHD to show more nuclear FoxO1 in cardiomyocytes from human IHD (n = 3) than that from NFH (n = 3) (Fig. 8A) . Immunohistochemical staining was performed on sections taken from mouse hearts and no FoxO1 signaling was detected in our hands. RT-PCR was performed on the RNA extracts, and Western blot was done on the protein extracts from the peri-infarct −/− led to shortening of QRS complex and increasing of P wave amplitude. Representative surface ECGs were recorded from conscious and unrestraint mice with or without cardiac-specific deletion of FoxO1 in Lead II. (A) QRS complex was shortened and P wave amplitude was increased in FoxO1 −/− mice. (B) Surface ECG parameters, heart rate, QRS duration, P wave amplitude, QTc-, PR-, and RR-intervals were analyzed. The data showed that QRS duration was significantly (p b 0.05) decreased and P wave amplitude was significantly (p b 0.05) increased in FoxO1 −/− mice, compared with those in FoxO1 +/+ mice but heart rate, QTc-, PR-, and RR-intervals were not changed.
(border zone) region (which was defined as the 2-mm area encircling the area of pathologic infarction) of the mouse hearts with permanent LAD ligation for one week and ventricular tissue from the shamcontrol group. Both Na V 1.5 protein and mRNA levels were significantly (p b 0.05 or p b 0.01) decreased in the peri-infarct region (n = 3), compared to those in the ventricular tissue from the control group (n = 3) (Fig. 8B ).
Discussion
This study uncovered that cardiac-specific deletion of FoxO1 in adult mice enhances voltage-gated Na + channel activity by increasing Na V 1.5
and β3 subunit expressions, increases the speed of Na + channel inactivation, and increases the recovery of Na + channel from inactivation.
This increase of Na + channel activity leads to an acceleration of cardiac depolarization as evidenced by the larger V max of action potentials recorded from FoxO1 −/− ventricular myocytes as well as the shortening of the QRS complex and the increase in P wave amplitude in surface ECGs recorded from conscious and unrestrained mice with cardiac deletion of FoxO1. Cardiac function was not changed by FoxO1 deletion. These in vivo findings support the conclusions from our previous in vitro studies that FoxO1 negatively regulates Na + channel activity by altering Na V 1.5 expression in HL-1 cardiomyocytes [27] . Furthermore, these studies showed that FoxO1 binds to the insulin response elements in the promoter of SCN5a and suppressed the promoter's activity, leading to the inhibition of Na V 1.5 expression [27] . In addition, our studies showed that the accumulation of FoxO1 in the cardiomyocyte nuclei of human IHD and decrease of Na V 1.5 expression in the peri-infarct (border-zone) of mouse hearts with myocardial infarction. This further indicates that Na V 1.5 is in vivo FoxO1 target during oxidative stress. It has been reported that cardiac-specific overexpression of the SCN5a gene did not significantly increase the surface density of the Na + channels in ventricular myocytes, indicating that Na V 1.5 localization to the membrane and formation of functional channels are limited [30] . Na + currents were increased in FoxO1 −/− ventricular myocytes, but our finding that FoxO1 deletion led to a significant increase in Na V 1.5 expression may not be able to explain the enhancement of the Na + channel activity. It has been shown that the β3 subunit can increase Na V 1.5 membrane expression and alter the channel kinetics in oocytes [31] . The subsequent promotion of Na + channel β3 subunit expression following FoxO1 deletion contributes to an increase in the Na V 1.5 surface expression and densities of the functional cardiac Na + channel.
The findings are most consistent with the decrease in I Na observed in cardiomyocytes of the β3 knockout mouse [32] . The acceleration of inactivation and the recovery from inactivation of the Na + channel are likely due to the increased β3 subunit expression, although steadystate activation and inactivation of this channel were not changed in FoxO1 −/− [31] . β3 regulating Na V 1.5 may have similar mechanisms by which β3 increases both expressions of the core-glycosylated form of Na V 1.7 and Na + channel activity [33] .
Na V 1.5, encoded by the SCN5a gene, is the main α subunit of the cardiac Na + channel and its activity determines cardiac excitability and electrical conduction. The importance of the cardiac Na + channel for normal cardiac electrical activity is emphasized by the occurrence of potentially lethal arrhythmias in the setting of inherited and acquired functional defects. Other extensive studies have been more focused on a large number of protein relationships, including β subunits, ankyrin-G, and MOGl interactions with Na V 1.5 [34] or concerned with posttranslational modifications, such as the effects of phosphorylation, glycosylation, S-nitrosylation, ubiquitination, and methylation on the function of the Na V 1.5 channel [35] . Knowledge of the mechanisms behind the regulation of Na V 1.5 expression at the transcriptional level is largely limited. Currently, it has been shown that four transcriptional NFKappaB and TBX5 directly affect the SCN5a promoter activity and alter Na V 1.5 expression [12, 24] . In vivo studies showed that TBX5 is only expressed in the mouse cardiac conducting cells and that specific deletion of TBX5 in these cells led to a severe reduction in cardiac conduction [24] . Accumulating evidence suggests that FoxO1 is the main isoform among FoxOs in the heart [26] and that it plays an important role in the regulation of cardiac function under different stresses [36] . It typically functions as a transcription activator and binds to the DNA promoter consensus sequences of target genes to upregulate their expression in response to cardiac stresses [36] . Both our in vitro [27] and in vivo studies are the first to show that FoxO1 negatively regulates Na V 1.5 expression. These findings strongly suggest that FoxO1 functions as a suppressor of SCN5a gene transcription. The mechanism of β3 subunit regulation by FoxO1 is unclear. FoxO proteins target a conserved DNA binding sequence, 5′-GTAAA (C/T)A-3′, or insulin response element (IRE), 5′-CAAAA(C/T)A-3′ in the promoters of their target genes to affect these gene expressions. Analysis of the β3 promoter revealed that there are IREs, CAAAA(C/T)A, in mice and humans. It is possible that FoxO1 regulates β3 expression by affecting the promoter activity. Additional studies including promoter activity and chromatin immunoprecipitation assays will be pursued to reach a definite conclusion in the future. FoxO1 is a transcriptional factor and its nuclear localization is important for its transcriptional activity. The nuclear localization is determined by the status of FoxO1 phosphorylation [36] and acetylation [37] . Any physiological and pathological event may alter the FoxO1 nuclear localization, subsequently regulating Na V 1.5 expression. Previous studies showed that FoxO proteins were phosphorylated in thoracic aortic banding, induced cardiac hypertrophy, and by several hypertrophic ligands, and their transcriptional activity was changed through a mechanism involving the PI3K/Akt pathway [29] . Consistent with these findings, we previously reported that increased Na + current density was associated with higher Na V 1.5 protein levels and increased FoxO1 phosphorylation in mouse left ventricular hypertrophy and failure induced by transverse aortic constriction. Akt has been reported to phosphorylate FoxO1 at threonine 24, serine 256 and serine 319 and makes FoxO1 less localized in the nuclei [38] . This process potentially involves less FoxO1's suppressive effects on Na V 1.5 expression in mouse cardiac hypertrophy and failure [39] . Epidemiologic data indicate that ischemic heart disease (IHD), a leading cause of death worldwide, is responsible for 80% of fatal arrhythmias and includes conditions such as ventricular tachycardia and ventricular fibrillation [40] [41] [42] [43] . Current therapies for cardiac arrhythmias include pharmacologic intervention, A-V node ablation, and electronic devices, which target ion channels with varying degrees of success and sometimes with severe side effects. It is crucial to identify the signaling pathways involved in cardiac ion channel regulations for IHD. Our studies revealed that FoxO1 is significantly increased in the nuclei of human cardiomyocytes during chronic ischemic cardiomyopathy and that both mRNA and protein levels of Na V 1.5 are significantly decreased in the peri-infarct (border-zone) of mouse ventricles. Elevated levels of reactive oxygen species (ROS) in IHD [44] [45] [46] induced the nuclear localization of FoxO1 in both HL-1 [27] and rat neonatal cardiomyocytes [26] potentially through acetylation [37] and phosphorylation at serine 212 by mammalian sterile 20-like kinase 1 [47] and suppresses Na V 1.5 expression through FoxO1 mediation of the SCN5a promoter activity [27] . Our findings indicate that FoxO1 plays an important role in the regulation of Na V 1.5 expression in IHD.
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